Cathomen, Anton 1966-
Cathomen, Toni
Toni Cathomen professeur d'université suisse
VIAF ID: 280823984 ( Personal )
Permalink: http://viaf.org/viaf/280823984
Preferred Forms
- 100 1 _ ‡a Cathomen, Anton ‡d 1966-
- 100 1 _ ‡a Cathomen, Toni
-
-
- 100 1 _ ‡a Cathomen, Toni
- 100 0 _ ‡a Toni Cathomen ‡c professeur d'université suisse
4xx's: Alternate Name Forms (9)
5xx's: Related Names (8)
- 551 _ _ ‡a Berlin ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Charité - Universitätsmedizin Berlin ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Freiburg im Breisgau ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Freie Universität Berlin ‡b Fachbereich Humanmedizin ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Hannover ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Institut für Transfusionsmedizin und Gentherapie ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Klinikum Freiburg im Breisgau ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Medizinische Hochschule Hannover ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Adapter-mediated transduction with lentiviral vectors: A novel tool for cell-type-specific gene transfer | |
Adaptive immunity in genitourinary cancers | |
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH) | |
Allele-specific disruption of a common STAT3 autosomal dominant allele is not sufficient to restore downstream signaling in patient-derived T cells | |
Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells | |
An anti-PSMA immunotoxin reduces Mcl-1 and Bcl2A1 and specifically induces in combination with the BAD-like BH3 mimetic ABT-737 apoptosis in prostate cancer cells | |
Artificial Targets: a versatile cell-free platform to characterize CAR T cell function in vitro | |
Assessing the differential impact of chronic CMV and treated HIV infection on CD8+ T-cell differentiation in a matched cohort study: is CMV the key? | |
Automated generation of gene-edited CAR T cells at clinical scale | |
Biodegradable nanocarriers resembling extracellular vesicles deliver genetic material with the highest efficiency to various cell types | |
Cell-based models of "cytokine release syndrome" endorse CD40L and granulocyte–macrophage colony-stimulating factor knockout in chimeric antigen receptor T cells as mitigation strategy | |
Chimerization enables gene synthesis and lentiviral delivery of customizable TALE-based effectors | |
Clinical genome editing to treat sickle cell disease - a brief update | |
CRISPR-Cas12a for highly efficient and marker-free targeted integration in human pluripotent stem cells | |
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma | |
CRISPR/Cas9 - einschneidende Revolution in der Gentechnik | |
Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells | |
Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells | |
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies | |
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1 | |
Efficient recombinase-mediated cassette exchange in hpscs to study the hepatocyte lineage reveals aavs1 locus-mediated transgene inhibition: CORRECTION | |
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy | |
Gene editing of hematopoietic stem cells restores T cell response in familial hemophagocytic lymphohistiocytosis | |
Gene therapy for STAT3-Associated Autosomal-Dominant Hyper-Ige-Syndrome (AD-HIES) using RNA-guided nucleases | |
Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN | |
Generation of safe CAR T cells to target B cell malignancies | |
Genome editing of SNAI1 gene in rhabdomyosarcoma: a novel model for studies of its role | |
Genome editing : the next step in gene therapy | |
Genome editing with TALEN, CRISPR-Cas9 and CRISPR-Cas12a in combination with AAV6 homology donor restores T cell function for XLP | |
High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis | |
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells | |
HIV-1 promoter is gradually silenced when integrated into BACH2 in Jurkat T-cells | |
Hypoxia enhances anti-fibrotic properties of extracellular vesicles derived from hiPSCs via the miR302b-3p/TGFβ/SMAD2 axis | |
Immunopathology caused by impaired CD8+ T‐cell responses | |
Improved specificity and safety of anti-hepatitis B virus TALENs using obligate heterodimeric fokI nuclease domains | |
Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA | |
Inhibition of the mouse double minute 2 protein promotes antileukemia immunity in human acute myeloid leukemia cells | |
Modeling MyD88 deficiency In vitro provides new insights in its function | |
Natural history of Pearson syndrome | |
Natural killer cells generated from human induced pluripotent stem cells mature to CD56brightCD16+NKp80+/-in-vitro and express KIR2DL2/DL3 and KIR3DL1 | |
A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa | |
A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells | |
Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa | |
Pre-clinical development of HIV resistant genome edited human CD4+ T cells | |
Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection | |
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi | |
PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model | |
Regulation of human early B lymphopoiesis | |
Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia | |
scope for thalassemia gene therapy by disruption of aberrant regulatory elements | |
T-CAST: An optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds | |
TALEN-mediated functional correction of human iPSC-derived macrophages in context of hereditary pulmonary alveolar proteinosis | |
TALEN mediated gene editing in a mouse model of Fanconi anemia | |
TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity | |
Targeted gene transfer to enhance safety and efficacy of immunotherapy | |
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model | |
Targeted integration of a super-exon into the CFTR locus leads to functional correction of a cystic fibrosis cell line model | |
Targeted integration of inducible Caspase-9 in human iPSCs allows efficient in vitro clearance of iPSCs and iPSC-macrophages | |
Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells | |
Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients | |
Tracing the specificity of CRISPR-Cas nucleases in clinically relevant human cells | |
Transcriptomic Landscape and Functional Characterization of Human Induced Pluripotent Stem Cell-Derived Limbal Epithelial Progenitor Cells | |
Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells |